Cynthia Villarreal-Garza1, Alejandro Mohar2, Juan Enrique Bargallo-Rocha3, Federico Lasa-Gonsebatt3, Nancy Reynoso-Noverón3, Juan Matus-Santos3, Paula Cabrera3, Claudia Arce-Salinas3, Fernando Lara-Medina3, Alberto Alvarado-Miranda3, María Teresa Ramírez-Ugalde3, Enrique Soto-Perez-de-Celis4. 1. Departamento de Investigacion y de Tumores Mamarios del Instituto Nacional de Cancerologia, Mexico City, Mexico; Centro de Cancer de Mama del Hospital Zambrano Hellion, Tecnologico de Monterrey, Nuevo Leon, Mexico. 2. Departamento de Investigacion y de Tumores Mamarios del Instituto Nacional de Cancerologia, Mexico City, Mexico; Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología e Instituto de Biomédicas, UNAM, Mexico City, Mexico. 3. Departamento de Investigacion y de Tumores Mamarios del Instituto Nacional de Cancerologia, Mexico City, Mexico. 4. Departamento de Investigacion y de Tumores Mamarios del Instituto Nacional de Cancerologia, Mexico City, Mexico; Cancer Care in the Elderly Clinic, Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Electronic address: enriquesotopc@yahoo.com.
Abstract
INTRODUCTION: Young age represents an adverse prognostic factor in breast cancer (BC), and young women present with more advanced and aggressive disease. In Latin America, BC is increasing in young women, and there is a lack of information regarding the characteristics and outcomes of this patient population. PATIENTS AND METHODS: We retrospectively analyzed a database of 4315 women treated for BC at a single institution. We compared clinical characteristics, treatment, and survival between women ≤ 40 and > 40 years of age. Survival analyses were performed for each molecular subtype. RESULTS: A total of 662 women (15.3%) were ≤ 40 years old. Younger women had more advanced disease, higher grade, and a larger proportion of luminal B and triple-negative tumors (P < .001). At 5 years, both disease-free and overall survival (OS) were lower in younger women, although there were no differences after adjusting for stage. Five-year OS was worse for young women with hormone receptor-positive, human epidermal growth factor receptor 2-negative subtype (82% vs. 87.1%; P = .03), but not for those with human epidermal growth factor receptor 2-positive or triple-negative disease. This difference can be attributed to luminal B tumors, which showed a worse 5-year OS in younger women (79.1% vs. 85.2%; P = .03). CONCLUSION: Although young Mexican patients with BC have more aggressive disease at presentation than older women, only those with luminal B tumors have a worse survival after adjusting for stage. Strategies aimed at downstaging the disease and at improving the treatment of luminal B tumors in this population are needed.
INTRODUCTION: Young age represents an adverse prognostic factor in breast cancer (BC), and young women present with more advanced and aggressive disease. In Latin America, BC is increasing in young women, and there is a lack of information regarding the characteristics and outcomes of this patient population. PATIENTS AND METHODS: We retrospectively analyzed a database of 4315 women treated for BC at a single institution. We compared clinical characteristics, treatment, and survival between women ≤ 40 and > 40 years of age. Survival analyses were performed for each molecular subtype. RESULTS: A total of 662 women (15.3%) were ≤ 40 years old. Younger women had more advanced disease, higher grade, and a larger proportion of luminal B and triple-negative tumors (P < .001). At 5 years, both disease-free and overall survival (OS) were lower in younger women, although there were no differences after adjusting for stage. Five-year OS was worse for young women with hormone receptor-positive, humanepidermal growth factor receptor 2-negative subtype (82% vs. 87.1%; P = .03), but not for those with humanepidermal growth factor receptor 2-positive or triple-negative disease. This difference can be attributed to luminal B tumors, which showed a worse 5-year OS in younger women (79.1% vs. 85.2%; P = .03). CONCLUSION: Although young Mexican patients with BC have more aggressive disease at presentation than older women, only those with luminal B tumors have a worse survival after adjusting for stage. Strategies aimed at downstaging the disease and at improving the treatment of luminal B tumors in this population are needed.
Authors: María Teresa Martínez; Sara S Oltra; María Peña-Chilet; Elisa Alonso; Cristina Hernando; Octavio Burgues; Isabel Chirivella; Begoña Bermejo; Ana Lluch; Gloria Ribas Journal: Breast Cancer (Auckl) Date: 2019-02-20
Authors: Bruna M Sugita; Silma R Pereira; Rodrigo C de Almeida; Mandeep Gill; Akanksha Mahajan; Anju Duttargi; Saurabh Kirolikar; Paolo Fadda; Rubens S de Lima; Cicero A Urban; Kepher Makambi; Subha Madhavan; Simina M Boca; Yuriy Gusev; Iglenir J Cavalli; Enilze M S F Ribeiro; Luciane R Cavalli Journal: Oncotarget Date: 2019-10-22
Authors: Maria Alice Franzoi; Daniela D Rosa; Facundo Zaffaroni; Gustavo Werutsky; Sérgio Simon; José Bines; Carlos Barrios; Eduardo Cronemberger; Geraldo Silva Queiroz; Vladmir Cordeiro de Lima; Ruffo Freitas Júnior; José Couto; Karla Emerenciano; Heloísa Resende; Susanne Crocamo; Tomás Reinert; Brigitte Van Eyli; Yeni Nerón; Vanessa Dybal; Nicolas Lazaretti; Rita de Cassia Costamillan; Diocésio Alves Pinto de Andrade; Clarissa Mathias; Giovana Zerwes Vacaro; Giuliano Borges; Alessandra Morelle; Carlos Alberto Sampaio Filho; Max Mano; Pedro E R Liedke Journal: J Glob Oncol Date: 2019-11
Authors: Cynthia Villarreal-Garza; Alejandra Platas; Melina Miaja; Alan Fonseca; Fernanda Mesa-Chavez; Marisol Garcia-Garcia; Judy-Anne Chapman; Edna A Lopez-Martinez; Claudia Pineda; Alejandro Mohar; Carmen L Galvez-Hernandez; Andrea Castro-Sanchez; Bertha-Alejandra Martinez-Cannon; Regina Barragan-Carrillo; Jose F Muñoz-Lozano; Paul Goss; Juan E Bargallo-Rocha; Dione Aguilar; Servando Cardona; Mauricio Canavati Journal: JCO Glob Oncol Date: 2020-03